



Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

September 3, 2026

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.

A webcast of the presentation will be available [here](#) beginning at 3:55 pm ET on Thursday, September 10, 2026 and will be posted on the Investors section of the Company's [website](#).

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK[®], the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on [LinkedIn](#) and [X](#).

CONTACT

Investors and Media:

Stéphane Paquette, PhD

Krystal Biotech

spaquette@krystalbio.com

